These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 729227)

  • 21. Endocrine therapies in breast and prostate cancer.
    Cancer Treat Res; 1988; 39():1-156. PubMed ID: 2908601
    [No Abstract]   [Full Text] [Related]  

  • 22. Synthesis and evaluation of B-, C-, and D-ring-substituted estradiol carboxylic acid esters as locally active estrogens.
    Labaree DC; Zhang JX; Harris HA; O'Connor C; Reynolds TY; Hochberg RB
    J Med Chem; 2003 May; 46(10):1886-904. PubMed ID: 12723952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormonal treatment in prostate cancer.
    Zbranca E; Preda C
    Endocrinologie; 1991; 29(1-2):91-7. PubMed ID: 1803495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunogenicity of synthetic sex hormones and thrombogenesis].
    Beaumont V; Beaumont JL
    Pathol Biol (Paris); 1985 Apr; 33(4):245-9. PubMed ID: 3892453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of steroids on immunologic function.
    Kaeberle ML
    Prog Clin Biol Res; 1984; 161():325-35. PubMed ID: 6483893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormonal modulation of plasminogen activator: an approach to prediction of human breast tumor responsiveness.
    Mira-y-Lopez R; Ossowski L
    Cancer Res; 1987 Jul; 47(13):3558-64. PubMed ID: 3107811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Letter: Hormonal contraception or therapy and altered immunity.
    Ablin RJ
    Lancet; 1975 Dec; 2(7947):1266. PubMed ID: 53764
    [No Abstract]   [Full Text] [Related]  

  • 28. [Luteinizing hormone-releasing hormone (LRH) agonist in the treatment of breast cancer, osteosarcoma and prostate carcinoma--analysis of 12 patients].
    Lu RK; Liu Y; Chen HY; Zhang L; He YY; Zhong W
    Zhonghua Zhong Liu Za Zhi; 1988 Jan; 10(1):70-2. PubMed ID: 3046877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.
    Dunn BK; Ford LG
    Eur J Cancer Prev; 2007 Jun; 16(3):232-42. PubMed ID: 17415094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cancer of the breast in patients having prostatic cancer treated with estrogens. Report of three cases (author's transl)].
    Dore B; Dombriz M; Denis P; Darracq-Paries JC; Barbier J; Aubert J
    J Urol (Paris); 1982; 88(4):247-52. PubMed ID: 7108255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormonal treatment of metastatic bone cancer].
    Tubiana-Hulin M
    Rev Rhum Mal Osteoartic; 1990 Nov; 57(11):821-7. PubMed ID: 2291074
    [No Abstract]   [Full Text] [Related]  

  • 33. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers.
    Rau KM; Kang HY; Cha TL; Miller SA; Hung MC
    Endocr Relat Cancer; 2005 Sep; 12(3):511-32. PubMed ID: 16172190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aspects for hormone therapy in prostate cancer].
    Gorski J; Böhm WD; Kelly LU
    Z Urol Nephrol; 1981 Sep; 74(9):635-41. PubMed ID: 7314984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal epidemiology of prostatic cancer.
    Ablin RJ
    Med J Aust; 1977 Mar; 1(13):462-4. PubMed ID: 865362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Estrogen popular again in prostatic cancer?].
    Hedlund PO
    Lakartidningen; 1992 Oct; 89(42):3467-9. PubMed ID: 1435047
    [No Abstract]   [Full Text] [Related]  

  • 38. Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms.
    Schally AV; Redding TW; Comaru-Schally AM
    Cancer Treat Rep; 1984 Jan; 68(1):281-9. PubMed ID: 6362868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention.
    Jordan VC
    Cancer Res; 2009 Feb; 69(4):1243-54. PubMed ID: 19208829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of short-term estradiol therapy on clotting and inflammatory markers in older men receiving hormonal suppression therapy for prostate cancer.
    Taxel P; Luthra P; Fall PM; Dauser D
    Aging Male; 2008 Jun; 11(2):71-5. PubMed ID: 18570058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.